Molecular determinants of response to PD-L1 blockade across tumor types

PD-L1 immune checkpoint inhibition has been used for several tumour types. Here, the authors use immunohistochemistry, tumour mutation burden and RNA-seq data from 366 patients with different indications to identify molecular signatures of response to atezolizumab and reveal pathway heterogeneity an...

Full description

Bibliographic Details
Main Authors:	Romain Banchereau, Ning Leng, Oliver Zill, Ethan Sokol, Gengbo Liu, Dean Pavlick, Sophia Maund, Li-Fen Liu, Edward Kadel, Nicole Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe June Assaf, Daniel Bower, Namrata Patil, Mark McCleland, David Shames, Luciana Molinero, Mahrukh Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti Hegde, Thomas Powles
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-06-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-021-24112-w

id	doaj-ae29efdfced64f11b4172bdb2e1a8bde
record_format	Article
spelling	doaj-ae29efdfced64f11b4172bdb2e1a8bde2021-06-27T11:12:46ZengNature Publishing GroupNature Communications2041-17232021-06-0112111110.1038/s41467-021-24112-wMolecular determinants of response to PD-L1 blockade across tumor typesRomain Banchereau0Ning Leng1Oliver Zill2Ethan Sokol3Gengbo Liu4Dean Pavlick5Sophia Maund6Li-Fen Liu7Edward Kadel8Nicole Baldwin9Suchit Jhunjhunwala10Dorothee Nickles11Zoe June Assaf12Daniel Bower13Namrata Patil14Mark McCleland15David Shames16Luciana Molinero17Mahrukh Huseni18Shomyseh Sanjabi19Craig Cummings20Ira Mellman21Sanjeev Mariathasan22Priti Hegde23Thomas Powles24GenentechGenentechGenentechFoundation MedicineGenentechFoundation MedicineGenentechGenentechGenentechBaylor Institute for Immunology ResearchGenentechGenentechGenentechGenentechGenentechGenentechGenentechGenentechGenentechGenentechGenentechGenentechGenentechFoundation MedicineBarts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of LondonPD-L1 immune checkpoint inhibition has been used for several tumour types. Here, the authors use immunohistochemistry, tumour mutation burden and RNA-seq data from 366 patients with different indications to identify molecular signatures of response to atezolizumab and reveal pathway heterogeneity and the involvement of non-immune pathways.https://doi.org/10.1038/s41467-021-24112-w
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Romain Banchereau Ning Leng Oliver Zill Ethan Sokol Gengbo Liu Dean Pavlick Sophia Maund Li-Fen Liu Edward Kadel Nicole Baldwin Suchit Jhunjhunwala Dorothee Nickles Zoe June Assaf Daniel Bower Namrata Patil Mark McCleland David Shames Luciana Molinero Mahrukh Huseni Shomyseh Sanjabi Craig Cummings Ira Mellman Sanjeev Mariathasan Priti Hegde Thomas Powles
spellingShingle	Romain Banchereau Ning Leng Oliver Zill Ethan Sokol Gengbo Liu Dean Pavlick Sophia Maund Li-Fen Liu Edward Kadel Nicole Baldwin Suchit Jhunjhunwala Dorothee Nickles Zoe June Assaf Daniel Bower Namrata Patil Mark McCleland David Shames Luciana Molinero Mahrukh Huseni Shomyseh Sanjabi Craig Cummings Ira Mellman Sanjeev Mariathasan Priti Hegde Thomas Powles Molecular determinants of response to PD-L1 blockade across tumor types Nature Communications
author_facet	Romain Banchereau Ning Leng Oliver Zill Ethan Sokol Gengbo Liu Dean Pavlick Sophia Maund Li-Fen Liu Edward Kadel Nicole Baldwin Suchit Jhunjhunwala Dorothee Nickles Zoe June Assaf Daniel Bower Namrata Patil Mark McCleland David Shames Luciana Molinero Mahrukh Huseni Shomyseh Sanjabi Craig Cummings Ira Mellman Sanjeev Mariathasan Priti Hegde Thomas Powles
author_sort	Romain Banchereau
title	Molecular determinants of response to PD-L1 blockade across tumor types
title_short	Molecular determinants of response to PD-L1 blockade across tumor types
title_full	Molecular determinants of response to PD-L1 blockade across tumor types
title_fullStr	Molecular determinants of response to PD-L1 blockade across tumor types
title_full_unstemmed	Molecular determinants of response to PD-L1 blockade across tumor types
title_sort	molecular determinants of response to pd-l1 blockade across tumor types
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2021-06-01
description	PD-L1 immune checkpoint inhibition has been used for several tumour types. Here, the authors use immunohistochemistry, tumour mutation burden and RNA-seq data from 366 patients with different indications to identify molecular signatures of response to atezolizumab and reveal pathway heterogeneity and the involvement of non-immune pathways.
url	https://doi.org/10.1038/s41467-021-24112-w
work_keys_str_mv	AT romainbanchereau moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT ningleng moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT oliverzill moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT ethansokol moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT gengboliu moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT deanpavlick moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT sophiamaund moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT lifenliu moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT edwardkadel moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT nicolebaldwin moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT suchitjhunjhunwala moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT dorotheenickles moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT zoejuneassaf moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT danielbower moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT namratapatil moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT markmccleland moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT davidshames moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT lucianamolinero moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT mahrukhhuseni moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT shomysehsanjabi moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT craigcummings moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT iramellman moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT sanjeevmariathasan moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT pritihegde moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes AT thomaspowles moleculardeterminantsofresponsetopdl1blockadeacrosstumortypes
_version_	1721358175514394624

Molecular determinants of response to PD-L1 blockade across tumor types

Similar Items